Loading…
Alector, Inc. is projected to rise to $2.22 by 2027, a +38% move from its current price of $1.61. ALEC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.54 | $1.61 | $1.68 | +0.08% |
| Jul 14 | $1.52 | $1.61 | $1.72 | +0.15% |
| Jul 15 | $1.50 | $1.61 | $1.74 | +0.23% |
| Jul 16 | $1.48 | $1.61 | $1.76 | +0.30% |
| Jul 17 | $1.46 | $1.62 | $1.78 | +0.38% |
| Jul 18 | $1.45 | $1.62 | $1.80 | +0.45% |
| Jul 19 | $1.44 | $1.62 | $1.82 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.44 | $1.62 | $1.82 | +0.53% |
| Week 2 | $1.38 | $1.63 | $1.92 | +1.06% |
| Week 3 | $1.34 | $1.64 | $2.00 | +1.59% |
| Week 4 | $1.30 | $1.64 | $2.08 | +2.13% |
| Week 5 | $1.27 | $1.65 | $2.15 | +2.67% |
| Week 6 | $1.25 | $1.66 | $2.21 | +3.21% |
| Week 7 | $1.23 | $1.67 | $2.27 | +3.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alector, Inc. is a clinical stage biotechnology company focused on counteracting the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations.
The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC is currently trading at $1.64 with a market capitalization of $181.53M and a rank of 3900. The current price position sits within a broader forecast that shows a multi-year bullish trajectory after a neutral start in 2026, with average prices rising from $1.64 in 2026 to $2.56 by 2030 and continuing to a long-term average of $8.60 by 2050. The forecast also presents a sequence of rising max values, culminating in a max of $19.79 by 2050.
This profile reflects the asset’s current market stance and its long-range outlook, including year-by-year average prices and the implied ROI across selected years. The numbers indicate a potential path to upside over time, tempered by near-term neutrality.
A major floor 33.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 34.2% above — a clean break opens room to run.
A major ceiling 68.0% above — clearing it would confirm fresh momentum.
Key ALEC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALEC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.79 | Sell | $1.75 | Sell |
| MA 10 | $1.90 | Sell | $1.81 | Sell |
| MA 20 | $1.78 | Sell | $1.84 | Sell |
| MA 50 | $1.98 | Sell | $1.94 | Sell |
| MA 100 | $2.12 | Sell | $2.00 | Sell |
| MA 200 | $2.00 | Sell | $2.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.04 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -72.44 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -12.02 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 23.24 | Buy |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 1.65 | Sell |
| ADX (14) | 18.22 | Neutral |
| ATR (14) | 0.07 | Info |
The near-term picture is neutral. The RSI14 sits at 40, and the short-term moving averages sit close to the current price, with SMA50 at $2.00 and SMA200 at $2.01.
In the 30-day window, the price has moved between a low of $1.21 and a high of $2.20. Support is identified at $1.48 and resistance at $2.21, framing a modest trading range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.48 | $1.61 | $2.38 | 0% | Neutral | |
| $1.67 | $2.22 | $3.18 | +38% | Bullish | |
| $1.86 | $2.60 | $3.93 | +61% | Bullish | |
| $1.72 | $2.51 | $3.96 | +56% | Bullish | |
| $1.69 | $2.54 | $4.16 | +58% | Bullish | |
| $1.58 | $2.47 | $4.16 | +54% | Bullish | |
| $1.45 | $2.33 | $4.04 | +45% | Bullish | |
| $1.94 | $3.23 | $5.73 | +101% | Bullish | |
| $2.18 | $3.73 | $6.76 | +131% | Bullish | |
| $2.06 | $3.64 | $6.73 | +126% | Bullish | |
| $2.28 | $4.59 | $9.24 | +185% | Bullish | |
| $3.96 | $8.80 | $19.99 | +447% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.48 | $1.61 | $1.95 | +0.00% |
| August 2026 | $1.34 | $1.60 | $1.99 | -0.50% |
| September 2026 | $1.42 | $1.72 | $2.18 | +7.65% |
| October 2026 | $1.50 | $1.84 | $2.36 | +6.76% |
| November 2026 | $1.46 | $1.81 | $2.35 | -1.81% |
| December 2026 | $1.45 | $1.81 | $2.38 | +0.03% |
Click any year to see its month-by-month ALEC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ALEC is projected to trade between $1.48 and $2.38, averaging $1.61 — a potential gain of 0% from today's $1.61. Price action looks broadly range-bound.
Alector, Inc.'s 2027 outlook centres on $2.22, within a $1.67 to $3.18 range. That is up +38% on the projected 2026 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ALEC could reach as high as $3.93, with a base case around $2.60 and support toward $1.86 — roughly +61% from $1.61. Momentum favours further upside here.
Expect ALEC to range from $1.72 to $3.96 through 2029. The $2.51 average target implies a +56% move from current prices. That is -3% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The ALEC price prediction for 2030 points to an average of $2.54 (low $1.69, high $4.16) — a potential gain of +58% on today's $1.61. Momentum favours further upside here.
In 2031, ALEC is projected to trade between $1.58 and $4.16, averaging $2.47 — a potential gain of +54% from today's $1.61. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Alector, Inc.'s 2032 outlook centres on $2.33, within a $1.45 to $4.04 range. That is -6% versus the projected 2031 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2033, ALEC could reach as high as $5.73, with a base case around $3.23 and support toward $1.94 — roughly +101% from $1.61. Buyers look set to stay in control over this stretch.
Expect ALEC to range from $2.18 to $6.76 through 2034. The $3.73 average target implies a +131% move from current prices. That is up +15% on the projected 2033 average. Momentum favours further upside here.
The ALEC price prediction for 2035 points to an average of $3.64 (low $2.06, high $6.73) — a potential gain of +126% on today's $1.61. Buyers look set to stay in control over this stretch.
In 2040, ALEC is projected to trade between $2.28 and $9.24, averaging $4.59 — a potential gain of +185% from today's $1.61. That is up +26% on the projected 2035 average. Momentum favours further upside here.
Alector, Inc.'s 2050 outlook centres on $8.80, within a $3.96 to $19.99 range. That is up +92% on the projected 2040 average. That marks a +447% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALEC today (≈ 621.118012 ALEC) could be worth
$5,467.79
+$4,467.79 (+447%) by 2050 · US Dollar
Based on the average projected ALEC price of $8.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALECwould be worth at today's price.
$1,000 invested in ALEC on Jul 10, 2025 (≈ 581.395339 ALEC) would be worth
$936.05
-$63.95 (-6.4%) today · 0.94× · US Dollar
Based on a ALEC entry price of $1.72 vs. today's $1.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.06 | $781.55 | -21.8% |
| 1 month ago | $1.52 | $1,059.21 | +5.9% |
| 3 months ago | $2.45 | $657.14 | -34.3% |
| 6 months ago | $1.84 | $875 | -12.5% |
| 1 year ago | $1.72 | $936.05 | -6.4% |
| All time (5.0y) ago | $37.31 | $43.15 | -95.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALEC forecast.
Our base-case forecast reaches $3.20 around 2033.
Implied market cap at $3.20: $355.28M
Over the multi-year horizon, the forecast shows a bullish tilt from 2027 onward. The 2027 average is $2.25, 2028 $2.63, 2029 $2.54, and 2030 $2.56, with 2031 $2.46 and 2032 $2.32, leading into 2033 at $3.19 and 2034 at $3.68, then 2035 at $3.61.
By 2040, the average rises to $4.44 with a max of $9.06 and an implied ROI of 171.8. By 2050, the average reaches $8.60 with a max of $19.79 and an implied ROI of 426.1. Sentiment remains BULLISH across the later years, with steadily expanding price targets, though these are estimates and not guarantees.
These figures illustrate a potential upside path that depends on future market conditions and execution, and they should be interpreted as estimates rather than financial advice.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $2.56, with a min of $1.68 and a max of $4.22. The implied ROI is 56.4 and the sentiment is BULLISH.
The forecast shows a bullish sentiment from 2027 onward, with rising averages and positive ROI values (e.g., 37.6 in 2027, 61.1 in 2028, 55.5 in 2029, and 56.4 in 2030). In 2026 the average is $1.64 and the ROI is 0, indicating a neutral near-term view.
Yes. The 2050 max forecast is $19.79, which surpasses $10, while the 2040 max forecast is $9.06, which is below $10. This suggests $10 could be reached by 2050 under the max scenario.
Current price is $1.64 and market cap is $181.53M.
The 30-day range is $1.21 to $2.20. The near-term support is $1.48 and resistance is $2.21.
Alector, Inc. Community Discussion
0Share your Alector, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.